New experimental drug SYH2072 tested in humans for the first time
NCT ID NCT07647783
First seen Jun 20, 2026 · Last updated Jun 22, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental drug called SYH2072 in 112 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo as single or multiple doses. The study aims to gather basic safety information before the drug can be tested in patients with a disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anzhen Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SYH2072 tablets
What this could lead to
If this early study shows the drug is safe, it could pave the way for future trials testing SYH2072 in patients with a specific disease.
What could go wrong
This is a very early Phase 1 trial in healthy people, not patients. The drug may prove unsafe or ineffective in later studies. Side effects are unknown.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.